BioAtla is a biopharmaceutical company that specializes in antibody-based therapeutics for solid tumor cancer treatment. The lead candidate product, BA3011, is a CAB ADC used to address soft tissue sarcoma, bone sarcoma, NSCLC, and ovarian cancer. BioAtla has also developed BA3021 and BA3071 for multiple solid tumor target areas, including melanoma, bladder cancer, small cell lung cancer, ovarian cancer, and renal cell carcinoma.